Skip to content

Serotonin research published in 2007

28 studies whose primary subject is serotonin were published in 2007, down from 30 in 2006. Newest first. Back to the serotonin overview

Studies

MDMA self‐administration in rats: acquisition, progressive ratio responding and serotonin transporter binding

European Journal of Neuroscience November 16, 2007 Susan Schenk, Lincoln S. Hely, Barbara Lake et al. 113 citations

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) self‐administration has been shown in animals with extensive drug histories, but only a small number of studies have examined high rates of responding maintained by MDMA in previously drug‐naïve animals. In the present study, influence of dose (0.25 or 1.0 mg/kg/infusion) on the acquisition of MDMA self‐administration was measured during daily...

DOI: 10.1111/j.1460-9568.2007.05932.x (opens in new tab) MDMA Self-administration Pharmacology Citalopram +2

Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor.

Molecular Pharmacology November 2007 Michael R Braden, David E Nichols

We assessed the relative importance of two serine residues located near the top of transmembrane helix 5 of the human 5-HT(2A) receptor, comparing the wild type with S5.43(239)A or S5.46(242)A mutations. Using the ergoline lysergic acid diethylamide (LSD), and a series of substituted tryptamine and phenethylamine 5-HT(2A) receptor agonists, we found that Ser5.43(239) is more critical for...

Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex

Journal of Neuroscience October 24, 2007 Francis Rodriguez Bambico, Noam Katz, Guy Debonnel et al. 325 citations

Preclinical and clinical studies show that cannabis modulates mood and possesses antidepressant-like properties, mediated by the agonistic activity of cannabinoids on central CB1 receptors (CB1Rs). The action of CB1R agonists on the serotonin (5-HT) system, the major transmitter system involved in mood control and implicated in the mechanism of action of antidepressants, remains however poorly...

Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens.

Proceedings of the National Academy of Sciences October 9, 2007 Alexandra Jean, Grégory Conductier, Christine Manrique et al.

Anorexia nervosa is a growing concern in mental health, often inducing death. The potential neuronal deficits that may underlie abnormal inhibitions of food intake, however, remain largely unexplored. We hypothesized that anorexia may involve altered signaling events within the nucleus accumbens (NAc), a brain structure involved in reward. We show here that direct stimulation of serotonin...

Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.

Journal of Biological Chemistry October 5, 2007 Miriam T Jacobs, Yuan-Wei Zhang, Scott D Campbell et al. 149 citations

Ibogaine, a hallucinogenic alkaloid with purported anti-addiction properties, inhibited serotonin transporter (SERT) noncompetitively by decreasing V(max) with little change in the K(m) for serotonin (5-HT). Ibogaine also inhibited binding to SERT of the cocaine analog 2beta-2-carbomethoxy-3-(4-[(125)I]iodophenyl)tropane. However, inhibition of binding was competitive, increasing the apparent...

Agonist induced-phosphorylation of Galpha11 protein reduces coupling to 5-HT2A receptors.

Journal of Pharmacology and Experimental Therapeutics October 2007 Ju Shi, Katerina J Damjanoska, Rakesh K Singh et al.

We previously demonstrated that 24-h treatment with (-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI) causes phosphorylation of Galpha11 protein at serine 154 and that this phosphorylation causes desensitization of serotonin (5-HT) 2A receptor signaling in A1A1v cells (Shi et al., 2007). We now report that treatment of A1A1v cells with DOI for 24 h produces a greater reduction in the...

Psilocybin-induced stimulus control in the rat.

Pharmacology, Biochemistry, and Behavior October 1, 2007 Jerrold C Winter, K C Rice, D J Amorosi et al. 73 citations

Although psilocybin has been trained in the rat as a discriminative stimulus, little is known of the pharmacological receptors essential for stimulus control. In the present investigation rats were trained with psilocybin and tests were then conducted employing a series of other hallucinogens and presumed antagonists. An intermediate degree of antagonism of psilocybin was observed following...

Comparative potencies of 3,4‐methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5‐HT transport in mammalian cell lines

British Journal of Pharmacology September 24, 2007 Therese Montgomery, Christophe Buon, S Eibauer et al. 33 citations

Background and purpose: Illegal ‘ecstasy’ tablets frequently contain 3,4‐methylenedioxymethamphetamine (MDMA)‐like compounds of unknown pharmacological activity. Since monoamine transporters are one of the primary targets of MDMA action in the brain, a number of MDMA analogues have been tested for their ability to inhibit [ 3 H]noradrenaline uptake into rat PC12 cells expressing the...

The stimulus effects of 8-OH-DPAT: evidence for a 5-HT2A receptor-mediated component.

Pharmacology, Biochemistry, and Behavior September 19, 2007 Chad J Reissig, Justin R Eckler, R A Rabin et al.

A previous investigation in our laboratory found that the stimulus effects of the 5-HT2A agonist, LSD, are potentiated by 5-HT1A receptor agonists including the prototypic agonist, 8-OH-DPAT. Also suggestive of behaviorally relevant interactions between 5-HT1A and 5-HT2A receptors are behavioral analyses of locomotor activity, head-twitch response, forepaw treading and production of the...

Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans

Psychopharmacology September 13, 2007 Olivia Carter, Felix Hasler, John D. Pettigrew et al. 150 citations

RationaleBinocular rivalry occurs when different images are simultaneously presented to each eye. During continual viewing of this stimulus, the observer will experience repeated switches between visual awareness of the two images. Previous studies have suggested that a slow rate of perceptual switching may be associated with clinical and drug-induced psychosis.ObjectivesThe objective of the...

Qualitative Review of Serotonin Syndrome, Ecstasy (MDMA) and the use of Other Serotonergic Substances: Hierarchy of Risk

Australian & New Zealand Journal of Psychiatry July 25, 2007 Edmund Silins, Jan Copeland, Paul Dillon 76 citations

Growth of the antidepressant market and widespread use of the illicit drug ecstasy (methylenedioxymethamphetamine; MDMA) creates a need to delineate the potential harms associated with the concomitant use of ecstasy and serotonergic pharmaceutical drugs. One such harm is serotonin syndrome. The study aimed to synthesize the risk of serotonin syndrome associated with the concomitant use of...

Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons.

Neurotoxicology July 2007 João Paulo Capela, Eduarda Fernandes, Fernando Remião et al.

3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") is a psychoactive and hallucinogenic drug of abuse. MDMA has been shown to produce neurotoxicity both in animals and humans. MDMA and other amphetamines induce serotonergic and dopaminergic terminal neurotoxicity and also neurodegeneration in areas including the cortex, hippocampus, striatum and thalamus. Herein, we investigated the...

Influence of PCPA and MDMA (ecstasy) on physiology, development and behavior in Drosophila melanogaster

European Journal of Neuroscience July 1, 2007 Sameera Dasari, Kert Viele, Amy Turner et al. 40 citations

Abstract The effects of para‐chlorophenylalanine (PCPA) and 3,4 methylenedioxy‐methamphetamine (MDMA, ‘ecstasy’) were investigated in relation to development, behavior and physiology in larval Drosophila . PCPA blocks the synthesis of serotonin (5‐HT) and MDMA is known to deplete 5‐HT in mammalian neurons; thus these studies were conducted primarily to target the serotonergic system. Treatment...

Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.

Journal of Pharmacology and Experimental Therapeutics June 2007 Pablo R Moya, Kelly A Berg, Manuel A Gutiérrez-Hernandez et al.

2,5-Dimethoxy-4-substituted phenylisopropylamines and phenethylamines are 5-hydroxytryptamine (serotonin) (5-HT)(2A/2C) agonists. The former are partial to full agonists, whereas the latter are partial to weak agonists. However, most data come from studies analyzing phospholipase C (PLC)-mediated responses, although additional effectors [e.g., phospholipase A(2) (PLA(2))] are associated with...

Studies on the mechanisms underlying amiloride enhancement of 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats.

European Journal of Pharmacology May 21, 2007 Beatriz Goñi-allo, Elena Puerta, Isabel Hervias et al. 13 citations

Amiloride and several of its congeners known to block the Na(+)/Ca(2+) and/or Na(+)/H(+) antiporters potentiate methamphetamine-induced neurotoxicity without altering methamphetamine-induced hyperthermia. We now examine whether amiloride also exacerbates 3,4-methylenedioxymethamphetamine (MDMA)-induced long-term serotonin (5-HT) loss in rats. Amiloride (2.5 mg/kg, every 2 h x 3, i.p.) given at...

Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis

Journal of Psychopharmacology May 1, 2007 Karsten Heekeren, Anna Neukirch, Jörg Daumann et al. 49 citations

Patients with schizophrenia exhibit diminished prepuLse inhibition (PPI) of the acoustic startle reflex and deficits in the attentional moduLation of PPI. Pharmacological challenges with hallucinogens are used as models for psychosis in both humans and animals. RemarkabLy, in contrast to the findings in schizophrenic patients and in animal hallucinogen modeLs of psychosis, previous studies with...

5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter.

Toxicology Letters April 5, 2007 Chiharu Sogawa, Norio Sogawa, J Tagawa et al. 47 citations

5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a synthetic orally active hallucinogenic tryptamine derivative, known also as Foxy or Foxy methoxy. However, few studies have examined its effects in vitro. In the present study, we investigated the actions of 5-MeO-DIPT against monoamine neurotransmitter transporters, including the transporters for dopamine (DAT), norepinephrine (NET), and...

A PET study of effects of chronic 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) on serotonin markers in Göttingen minipig brain

Synapse April 5, 2007 Paul Cumming, Mette Møller, Kjeld Benda et al. 28 citations

Abstract The psychostimulant 3,4‐methylendioxymethamphetamine (MDMA, “ecstasy”) evokes degeneration of telencephalic serotonin innervations in rodents, nonhuman primates, and human recreational drug users. However, there has been no alternative to nonhuman primates for studies of the cognitive and neurochemical consequences of serotonin depletion in a large‐bodied animal. Therefore, we used...

DOI: 10.1002/syn.20377 (opens in new tab) MDMA Ecstasy Neurochemical Serotonin transporter +3

The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.

European Journal of Pharmacology March 22, 2007 Fumiko Nagai, Ryouichi Nonaka, Kanako Satoh Hisashi Kamimura 277 citations

We developed a reproducible, simple, and small-scale method for determining the re-uptake and release of monoamines (dopamine, serotonin (5-HT) and norepinephrine) using rat brain synaptosomes. These assays were then applied to study the effects of different kinds of non-medically used psychoactive drugs on monoamine re-uptake and release. The phenethylamine derivatives, 4-fluoroamphetamine,...

DOI: 10.1016/j.ejphar.2006.11.075 (opens in new tab) Full text (opens in new tab) Serotonin Neurotransmission neurotransmitters Monoamines Dopamine +24

Is Recreational Ecstasy (MDMA) Use Associated with Higher Levels of Depressive Symptoms?

Journal of Psychoactive Drugs March 1, 2007 Casey R. Guillot 26 citations

Due to potential serotonergic deficits, 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) may cause long-term mood disruptions in recreational Ecstasy users. The purpose of this review is to evaluate the evidence for a relationship between recreational Ecstasy use and higher levels of depressive symptoms. Eleven out of 22 studies initially have reported significantly higher depression scores...